Compare Cart
  • Japanese
  • Korean
  • Traditional Chinese
  • Simplified Chinese
Cover Image
Market Research Report
Product code 
1040454

Central Nervous System (CNS) Biomarker Market 2021-2027
Published: | Orion Market Research Pvt Ltd | Delivery time: 2-3 business days

Price

Back to Top
Central Nervous System (CNS) Biomarker Market 2021-2027
Published: August 19, 2021
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Global Central Nervous System (CNS) Biomarker Market Size, Share &Trends Analysis Report By Application (Drug Discovery &Development, Personalized Medicine, Disease Risk Assessment, and Other), By Type (Safety Biomarker, Efficacy Biomarker, Predictive Biomarker, Prognostic Biomarker, and Validation Biomarker), and By End-User (Diagnostic Labs, Hospitals &Clinics, and, Research Centers) Forecast Period 2021-2027

The global CNS biomarker market is anticipated to grow at a significant CAGR of 15.5% during the forecast period (2021-2027). The central nervous system biomarkers market is predicted to rise due to an increase in pipeline research for the creation of biomarkers in various illness situations. As per the reports published by the American Cancer Society, in 2019, Biomarkers in Central Nervous System Tumors, specific diagnostic, prognostic, and predictive biomarkers have been discovered, and more are on the way. As a result, understanding specific biomarkers is critical for tailored treatment and follow-up.

The global CNS biomarker market is segmented based on application, type, and end-user. By application, the market is segmented into drug discovery &development, personalized medicine, disease risk assessment, and others. Further, based on the type segment, the market is segmented into safety biomarker, efficacy biomarker, predictive biomarker, prognostic biomarker, and validation biomarker. Moreover, based on the end-user segment, the market is segmented into diagnostic labs, hospitals and clinics, and research centers. Among the application segment, the personalized segment is anticipated to provide a lucrative growth opportunity to the market. The primary factor attributable to the segmental growth of the market is the rising cases of the nervous system and brain cancers, among others. Personalized medicine has widely been used as a diagnostic tool, that aids in recognizing the precised biomarker. For instance, in June 2020, Merck KGaA collaborated with Personalis, to develop biomarkers for offering cancer therapies. Additionally, through this partnership, Merck utilizes a cancer immunogenomics platform manufactured by Personalis.

Based on the regions, the CNS biomarker market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among the regions, the CNS biomarker market is estimated to experience the largest growth in the North America region. The major factors attributable to the growth of the regional growth include the growing incidence of chronic diseases in the countries such as the US and Canada. According to the report released by GLOBOCAN, in 2020, there were around 2,281,658 new cancer cases and 612,390 deaths have been reported, due to cancer in the US. The rising development of genomics and imaging systems will further drive the growth of the market.

Further, Eli Lilly and Company, Otsuka America Pharmaceutical Inc., Aposense, Banyan Biomarkers, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Fujirebio, Bio-Rad Laboratories, Inc., Pfizer Inc., Avacta Group PLC, and AppliedNeurosolutions, Inc., among others are some of the prominent players functioning in the global CNS Biomarker market. New product launches &developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market. For instance, in May 2020, Accure Therapeutics launched operations by initiating a series A funding worth $8.1 million. The funding has been led by Alta Life Sciences along with the Centre for Technological and Industrial Development (CDTI). Through these funding rounds, the company will manufacture new drugs for curing CNS diseases.

Research Methodology

The market study of the global CNS biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research-papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global CNS Biomarker Market Research and Analysis By Application

Global CNS Biomarker Market Research and Analysis By Type

Global CNS Biomarker Market Research and Analysis By End-User

The Report Covers

Comprehensive research methodology of the global CNS biomarker

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global CNS biomarker market

Insights about market determinants which are stimulating the global CNS biomarker market

Detailed and extensive market segments with regional distribution of forecast revenues

Extensive profiles and recent developments of the market players.

Product Code: OMR2024005

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global CNS Biomarkers Industry
  • Recovery Scenario of Global CNS Biomarkers Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Banyan Biomarkers, Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Bio-Rad Laboratories, Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Eli Lilly & Co.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. F. Hoffmann-La Roche Ltd
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Thermo Fisher Scientific, Inc.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global CNS Biomarker Market By Application
    • 5.1.1. Drug Discovery & Development
    • 5.1.2. Personalized Medicine
    • 5.1.3. Disease Risk Assessment
    • 5.1.4. Other
  • 5.2. Global CNS Biomarker Market By Type
    • 5.2.1. Safety Biomarker
    • 5.2.2. Efficacy Biomarker
    • 5.2.3. Predictive Biomarker
    • 5.2.4. Prognostic Biomarker
    • 5.2.5. Validation Biomarker
  • 5.3. Global CNS Biomarker Market By End User
    • 5.3.1. Diagnostic Labs
    • 5.3.2. Hospitals and Clinics
    • 5.3.3. Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc
  • 7.2. Adlyfe Inc.
  • 7.3. ADxNeuroSciences NV
  • 7.4. Altoida, Inc.
  • 7.5. Aposense Ltd.
  • 7.6. Applied NeuroSolutions, Inc.
  • 7.7. AstraZeneca Plc
  • 7.8. Avacta Group PLC
  • 7.9. Biogen Inc.
  • 7.10. Fujirebio Diagnostics, Inc. (Innogenetics)
  • 7.11. GlaxoSmithKline plc
  • 7.12. Iron Horse Diagnostics, Inc.
  • 7.13. Johnson & Johnson Services, Inc.
  • 7.14. Merck KGaA
  • 7.15. Metabolon, Inc.
  • 7.16. Neuraltus Pharmaceuticals, Inc.
  • 7.17. Novartis AG
  • 7.18. Otsuka America Pharmaceutical, Inc.
  • 7.19. Pfizer Inc.
  • 7.20. Takeda Pharmaceutical Company Ltd.

LIST OF TABLES

  • 1. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSISBY APPLICATION, 2020-2027 ($ MILLION)
  • 3. GLOBAL CNS BIOMARKER IN DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 4. GLOBAL CNS BIOMARKER IN PERSONALIZED MEDICAL MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 5. GLOBAL CNS BIOMARKER IN DISEASE RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 6. GLOBAL CNS BIOMARKER IN OTHER APPLICATION MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 7. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSISBY TYPE, 2020-2027 ($ MILLION)
  • 8. GLOBAL SAFETY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 9. GLOBAL EFFICACY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 10. GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 11. GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 12. GLOBAL VALIDATION BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)

13. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION

  • 14. GLOBAL CNS BIOMARKER IN DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 15. GLOBAL CNS BIOMARKER IN HOSPITALS &CLINICS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 16. GLOBAL CNS BIOMARKER IN RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 17. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BYGEOGRAPHY, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END-USER, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. EUROPEAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2020-2027 ($ MILLION)
  • 23. EUROPEAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 24. EUROPEAN CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 25. EUROPEAN CNS BIOMARKER MARKET RESEARCH AND ANALYSISBY COUNTRY, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD CNS BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY TYPE, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CNS BIOMARKER MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CNS BIOMARKERMARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CNS BIOMARKERMARKET, 2021-2027 (%)

4. GLOBAL CNS BIOMARKERMARKET SHARE BY APPLICATION 2020 VS 2027 (IN %)

5. GLOBAL CNS BIOMARKERMARKET SHARE BY TYPE,2020 VS 2027 (IN %)

6. GLOBAL CNS BIOMARKERMARKET SHARE BY END-USER,2020 VS 2027 (IN %)

7. GLOBAL CNS BIOMARKERMARKET SHARE BY APPLICATION,2020 VS 2027 (IN %)

8. GLOBAL CNS BIOMARKERMARKET SHAREBY GEOGRAPHY,2020 VS 2027 (IN %)

  • 9. GLOBAL CNS BIOMARKER IN DRUG DISCOVERY & DEVELOPMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 10. GLOBAL CNS BIOMARKER IN PERSONALIZED MEDICAL MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 11. GLOBAL CNS BIOMARKER IN DISEASE RISK ASSESSMENT MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 12. GLOBAL CNS BIOMARKER IN OTHER APPLICATION MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 13. GLOBAL SAFETY BIOMARKER MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 14. GLOBAL EFFICACY BIOMARKER MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 15. GLOBAL PREDICTIVE BIOMARKER MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 16. GLOBAL PROGNOSTIC BIOMARKER MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 17. GLOBAL VALIDATION BIOMARKER MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 18. GLOBAL CNS BIOMARKER IN DIAGNOSTIC LABS MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 19. GLOBAL CNS BIOMARKER IN HOSPITALS & CLINICS MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 20. GLOBAL CNS BIOMARKER IN RESEARCH CENTERS MARKET SHARE BY REGION, 2020 VS 2027(%)
  • 21. UNITED STATES CNS BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. CANADA CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 23. UK CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 24. GERMANY CNS BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. FRANCE CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 26. ITALY CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 27. ROE CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 28. CHINA CNS BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. INDIA CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 30. JAPAN CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 31. REST OF ASIA PACIFIC CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)
  • 32. REST OF WORLD CNS BIOMARKERMARKET SIZE, 2020-2027 ($ MILLION)